{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:03:37Z","timestamp":1793448217660,"version":"4.5.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Learning Objectives<\/jats:title>\n                    <jats:p>After completing this course, the reader will be able to: Assess patients with EBV-associated lymphoproliferative disorders.Describe the pathogenesis of the lymphoproliferative disorders linked to EBV infection.Evaluate EBV cell\u2013based immunotherapy for use in patients with EBV-associated lymphoproliferative disorders.<\/jats:p>\n                    <jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>\n                    <jats:p>Since its discovery as the first human tumor virus, Epstein-Barr virus (EBV) has been implicated in the development of a wide range of B-cell lymphoproliferative disorders, including Burkitt's lymphoma, classic Hodgkin's lymphoma, and lymphomas arising in immunocompromised individuals (post-transplant and HIV-associated lymphoproliferative disorders). T-cell lymphoproliferative disorders that have been reported to be EBV associated include a subset of peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphoma, extranodal nasal type natural killer\/T-cell lymphoma, and other rare histotypes. EBV encodes a series of products interacting with or exhibiting homology to a wide variety of antiapoptotic molecules, cytokines, and signal transducers, hence promoting EBV infection, immortalization, and transformation. However, the exact mechanism by which EBV promotes oncogenesis is an area of active debate. The focus of this review is on the pathology, diagnosis, classification, and pathogenesis of EBV-associated lymphomas. Recent advances in EBV cell\u2013based immunotherapy, which is beginning to show promise in the treatment of EBV-related disorders, are discussed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2008-0036","type":"journal-article","created":{"date-parts":[[2008,5,30]],"date-time":"2008-05-30T16:53:48Z","timestamp":1212166428000},"page":"577-585","source":"Crossref","is-referenced-by-count":215,"title":["EBV-Associated Lymphoproliferative Disorders: Classification and Treatment"],"prefix":"10.1093","volume":"13","author":[{"given":"Antonino","family":"Carbone","sequence":"first","affiliation":[{"name":"a Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Gloghini","sequence":"additional","affiliation":[{"name":"a Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampietro","family":"Dotti","sequence":"additional","affiliation":[{"name":"b Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"2021122208461976300_R1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2021122208461976300_R2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2006.05.010","article-title":"DNA viruses in human cancer: An integrated overview on fundamental mechanisms of viral carcinogenesis","volume":"247","author":"Elgui de Oliveira","year":"2007","journal-title":"Cancer Lett"},{"key":"2021122208461976300_R3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/jcp.2006.044586","article-title":"Epstein Barr virus-associated tumours: An update for the attention of the working pathologist","volume":"60","author":"Delecluse","year":"2007","journal-title":"J Clin Pathol"},{"key":"2021122208461976300_R4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/jcp.2007.047969","article-title":"Kaposi sarcoma-associated herpesvirus\/human herpesvirus 8 and lymphoproliferative disorders","volume":"60","author":"Du","year":"2007","journal-title":"J Clin Pathol"},{"key":"2021122208461976300_R5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1634\/theoncologist.12-5-569","article-title":"Primary effusion lymphoma","volume":"12","author":"Chen","year":"2007","journal-title":"The Oncologist"},{"key":"2021122208461976300_R6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1078-0432.CCR-0670-3","article-title":"Epstein-Barr virus and cancer","volume":"10","author":"Thompson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122208461976300_R7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1573394052952528","article-title":"EBV-associated tumors: Pathogenetic insights for improved disease monitoring and treatment","volume":"1","author":"Dolcetti","year":"2005","journal-title":"Curr Cancer Ther Rev"},{"key":"2021122208461976300_R8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.humpath.2007.05.020","article-title":"Epstein-Barr virus-associated lymphoproliferative disorders","volume":"38","author":"Rezk","year":"2007","journal-title":"Hum Pathol"},{"key":"2021122208461976300_R9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/(SICI)1096-9071(199605)49:1<7::AID-JMV2>3.0.CO;2-A","article-title":"Transcriptional expression of Epstein-Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinoma","volume":"49","author":"Sbih-Lammali","year":"1996","journal-title":"J Med Virol"},{"key":"2021122208461976300_R10","first-page":"107","volume-title":"The Human Herpesvirus","author":"Liebowitz","year":"1993"},{"key":"2021122208461976300_R11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00001622-199909000-00002","article-title":"Virus associated lymphomas","volume":"11","author":"Cesarman","year":"1999","journal-title":"Curr Opin Oncol"},{"key":"2021122208461976300_R12","first-page":"143","article-title":"Epstein-Barr virus infection and the pathogenesis of malignant lymphomas","volume":"30","author":"Niedobitek","year":"1997","journal-title":"Cancer Surv"},{"key":"2021122208461976300_R13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/mp.52.2.97","article-title":"Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases","volume":"52","author":"Hayes","year":"1999","journal-title":"Mol Pathol"},{"key":"2021122208461976300_R14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nri1201","article-title":"B cells under influence: Transformation of B cells by Epstein-Barr virus","volume":"3","author":"K\u00fcppers","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"2021122208461976300_R15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1286-4579(00)00282-3","article-title":"Regulation of cell growth and death by Epstein-Barr virus","volume":"2","author":"Wensing","year":"2000","journal-title":"Microbes Infect"},{"key":"2021122208461976300_R16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1651-2227.1998.tb01377.x","article-title":"Epstein-Barr virus infection and its role in the expanding spectrum of human diseases","volume":"87","author":"Okano","year":"1998","journal-title":"Acta Paediatr"},{"key":"2021122208461976300_R17","doi-asserted-by":"crossref","first-page":"14935","DOI":"10.1073\/pnas.0509988103","article-title":"Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc\u2013expressing Burkitt lymphoma cells","volume":"103","author":"Kelly","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208461976300_R18","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1002\/j.1460-2075.1996.tb00674.x","article-title":"Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice","volume":"15","author":"Wilson","year":"1996","journal-title":"EMBO J"},{"key":"2021122208461976300_R19","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1093\/emboj\/19.24.6742","article-title":"Epstein-Barr virus\u2013encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction","volume":"19","author":"Kitagawa","year":"2000","journal-title":"EMBO J"},{"issue":"suppl 5","key":"2021122208461976300_R20","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/annonc\/9.suppl_5.S5","article-title":"Epstein-Barr virus in Hodgkin's disease","volume":"9","author":"Chapman","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122208461976300_R21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bjc.1991.281","article-title":"Viral involvement in Hodgkin's disease: Detection of clonal type A Epstein-Barr virus genomes in tumor samples","volume":"64","author":"Gledhill","year":"1991","journal-title":"Br J Cancer"},{"key":"2021122208461976300_R22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood.V81.2.468.468","article-title":"Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: Association between B-type EBV and immunocompromise","volume":"81","author":"Boyle","year":"1993","journal-title":"Blood"},{"key":"2021122208461976300_R23","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.leu.2401097","article-title":"Epstein-Barr virus and Hodgkin's disease: Further evidence for the three disease hypothesis","volume":"12","author":"Armstrong","year":"1998","journal-title":"Leukemia"},{"key":"2021122208461976300_R24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells","volume":"184","author":"Kanzler","year":"1996","journal-title":"J Exp Med"},{"key":"2021122208461976300_R25","first-page":"912","article-title":"CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease","volume":"147","author":"Carbone","year":"1995","journal-title":"Am J Pathol"},{"key":"2021122208461976300_R26","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1200\/JCO.2005.55.013","article-title":"Molecular pathogenesis of Hodgkin's lymphoma","volume":"23","author":"Re","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208461976300_R27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V85.3.780.bloodjournal853780","article-title":"Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines","volume":"85","author":"Carbone","year":"1995","journal-title":"Blood"},{"key":"2021122208461976300_R28","first-page":"2319","article-title":"Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells","volume":"93","author":"Carbone","year":"1999","journal-title":"Blood"},{"key":"2021122208461976300_R29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00007890-196908000-00033","article-title":"Primary malignancy in patients undergoing immunosuppression for renal transplantation","volume":"8","author":"McKhann","year":"1969","journal-title":"Transplantation"},{"key":"2021122208461976300_R30","first-page":"106","article-title":"Malignant lymphomas in transplantation patients","volume":"1","author":"Penn","year":"1969","journal-title":"Transplant Proc"},{"key":"2021122208461976300_R31","first-page":"257","volume-title":"World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Borish","year":"2001"},{"key":"2021122208461976300_R32","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1978::AID-CNCR23>3.0.CO;2-P","article-title":"The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant","volume":"82","author":"Chadburn","year":"1998","journal-title":"Cancer"},{"key":"2021122208461976300_R33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0037-1963(03)70003-1","article-title":"Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases","volume":"40","author":"Cohen","year":"2003","journal-title":"Semin Hematol"},{"key":"2021122208461976300_R34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1034\/j.1399-3062.1999.010308.x","article-title":"The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease","volume":"1","author":"Hsieh","year":"1999","journal-title":"Transplant Infect Dis"},{"key":"2021122208461976300_R35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1034\/j.1399-3062.2001.003002060.x","article-title":"The Epstein-Barr virus and post-transplant lymphoproliferative disease: Interplay of immunosuppression, EBV, and the immune system in disease pathogenesis","volume":"3","author":"Tanner","year":"2001","journal-title":"Transplant Infect Dis"},{"key":"2021122208461976300_R36","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/intimm\/dxh099","article-title":"Determining virological, serological and immunological parameters of EBV infection in the development of PTLD","volume":"16","author":"Davis","year":"2004","journal-title":"Int Immunol"},{"key":"2021122208461976300_R37","first-page":"260","volume-title":"World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Raphael","year":"2001"},{"key":"2021122208461976300_R38","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"key":"2021122208461976300_R39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/000348949910800115","article-title":"AIDS-related plasmablastic lymphomas of the oral cavity and jaws: A diagnostic dilemma","volume":"108","author":"Carbone","year":"1999","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2021122208461976300_R40","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2141.2005.05613.x","article-title":"AIDS-related lymphomas: From pathogenesis to pathology","volume":"130","author":"Carbone","year":"2005","journal-title":"Br J Haematol"},{"key":"2021122208461976300_R41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000097459","article-title":"HHV-8-associated lymphoma: State-of-the-art review","volume":"117","author":"Carbone","year":"2007","journal-title":"Acta Haematol"},{"key":"2021122208461976300_R42","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122208461976300_R43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2141.1996.d01-1826.x","article-title":"Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions","volume":"94","author":"Carbone","year":"1996","journal-title":"Br J Haematol"},{"key":"2021122208461976300_R44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645","article-title":"Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus","volume":"88","author":"Nador","year":"1996","journal-title":"Blood"},{"key":"2021122208461976300_R45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<16::AID-GCC3>3.0.CO;2-F","article-title":"Genetic characterization of HHV-8\/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: Implications for disease pathogenesis and histogenesis","volume":"24","author":"Gaidano","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"2021122208461976300_R46","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1128\/JVI.79.2.1244-1251.2005","article-title":"Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association","volume":"79","author":"Fan","year":"2005","journal-title":"J Virol"},{"key":"2021122208461976300_R47","first-page":"189","volume-title":"World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue","author":"Jaffe","year":"2001"},{"key":"2021122208461976300_R48","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"2021122208461976300_R49","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208461976300_R50","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.onc.1209178","article-title":"Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas","volume":"25","author":"Ballester","year":"2006","journal-title":"Oncogene"},{"key":"2021122208461976300_R51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): A new diagnostic marker providing evidence that AITL derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2021122208461976300_R52","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"2021122208461976300_R53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/mp.52.6.307","article-title":"The Epstein-Barr virus and its association with human cancers","volume":"52","author":"Baumforth","year":"1999","journal-title":"Mol Pathol"},{"key":"2021122208461976300_R54","first-page":"45","volume-title":"IARC Monographs on the Evaluation of Carcinogenic Risks to Humans","author":"International Agency for Research on Cancer","year":"1997"},{"key":"2021122208461976300_R55","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","article-title":"Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS\/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting","volume":"68","author":"Paya","year":"1999","journal-title":"Transplantation"},{"key":"2021122208461976300_R56","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/j.1600-6143.2005.01002.x","article-title":"Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients","volume":"5","author":"Lee","year":"2005","journal-title":"Am J Transplant"},{"key":"2021122208461976300_R57","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood.V95.4.1502.004k40_1502_1505","article-title":"CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation","volume":"95","author":"Kuehnle","year":"2000","journal-title":"Blood"},{"issue":"suppl 1","key":"2021122208461976300_R58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/11.suppl_1.S113","article-title":"Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients","volume":"11","author":"Milpied","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122208461976300_R59","first-page":"618","article-title":"Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant","volume":"86","author":"Dotti","year":"2001","journal-title":"Haematologica"},{"key":"2021122208461976300_R60","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"key":"2021122208461976300_R61","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1600-6143.2004.00693.x","article-title":"Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease","volume":"5","author":"Savoldo","year":"2005","journal-title":"Am J Transplant"},{"key":"2021122208461976300_R62","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00007890-200210270-00007","article-title":"Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome","volume":"74","author":"Dotti","year":"2002","journal-title":"Transplantation"},{"key":"2021122208461976300_R63","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1200\/JCO.2005.08.074","article-title":"Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation","volume":"23","author":"Gross","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208461976300_R64","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.10595","article-title":"CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation","volume":"92","author":"Choquet","year":"2007","journal-title":"Haematologica"},{"issue":"suppl 4","key":"2021122208461976300_R65","first-page":"1","article-title":"European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient","volume":"17","author":"EBPG Expert Group on Renal Transplantation","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2021122208461976300_R66","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"2021122208461976300_R67","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208461976300_R68","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","article-title":"Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication","volume":"99","author":"Comoli","year":"2002","journal-title":"Blood"},{"key":"2021122208461976300_R69","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"key":"2021122208461976300_R70","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"key":"2021122208461976300_R71","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0140-6736(03)12777-8","article-title":"Hodgkin's lymphoma","volume":"361","author":"Yung","year":"2003","journal-title":"Lancet"},{"key":"2021122208461976300_R72","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208461976300_R73","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"key":"2021122208461976300_R74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1634\/theoncologist.8-1-83","article-title":"Immunotherapy for Epstein-Barr virus-associated cancers in children","volume":"8","author":"Straathof","year":"2003","journal-title":"The Oncologist"},{"key":"2021122208461976300_R75","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood-2004-08-3337","article-title":"Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis","volume":"105","author":"Dotti","year":"2005","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2008-0036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2008-0036","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/5\/577\/41831849\/oncolo_13_5_577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/5\/577\/41831849\/oncolo_13_5_577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T10:24:50Z","timestamp":1640168690000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/13\/5\/577\/6396654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,1]]},"references-count":75,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2008,5,1]]},"published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2008-0036","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,5,1]]},"published":{"date-parts":[[2008,5,1]]}}}